These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22122451)

  • 1. PPAR ligands and cardiovascular disorders: friend or foe.
    Balakumar P; Jagadeesh G
    Curr Mol Pharmacol; 2012 Jun; 5(2):219-23. PubMed ID: 22122451
    [No Abstract]   [Full Text] [Related]  

  • 2. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
    Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
    Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARs as targets for metabolic and cardiovascular diseases.
    Cheng PT; Mukherjee R
    Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR agonists, - Could tissue targeting pave the way?
    Bugge A; Holst D
    Biochimie; 2017 May; 136():100-104. PubMed ID: 27916640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
    Golledge J; Cullen B; Rush C; Moran CS; Secomb E; Wood F; Daugherty A; Campbell JH; Norman PE
    Atherosclerosis; 2010 May; 210(1):51-6. PubMed ID: 19926086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
    Maccallini C; Mollica A; Amoroso R
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):273-281. PubMed ID: 28315197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
    Rosenson RS
    Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR-gamma agonists: shifting attention from the belly to the heart?
    van Wijk JP; Rabelink TJ
    Arterioscler Thromb Vasc Biol; 2004 May; 24(5):798-800. PubMed ID: 15132970
    [No Abstract]   [Full Text] [Related]  

  • 16. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.
    Khuchua Z; Glukhov AI; Strauss AW; Javadov S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.
    Robinson JG
    Curr Atheroscler Rep; 2007 Jan; 9(1):64-71. PubMed ID: 17169249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
    Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.